Home › NDC Lookup › RxCUI directory › RxCUI 1000141

Medroxyprogesterone acetate 5 MG Oral Tablet — RxCUI 1000141

RxNorm drug concept · Semantic clinical drug
RxCUI 1000141 Semantic clinical drug · SCD ● Current RxNorm concept 12 FDA products 18 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1000141
Official nameMedroxyprogesterone acetate 5 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped12
Package NDCs mapped18
Reported Medicaid activity (SDUD)344,866 prescriptions · 52 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Medroxyprogesterone Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It prevents pregnancy. Depo-subQ Provera 104 is also used to manage pain from endometriosis. A healthcare professional gives it, so you do not inject it yourself.
  • Depo-subQ Provera 104 is given about every 12 to 14 weeks. If you cannot get it in that window, use another birth control method until your next injection. If more than 14 weeks pa...
  • Changes in your bleeding pattern are the most common, including spotting, irregular bleeding or no periods at all. Headache, weight gain and injection site soreness or lumps can al...
  • This medicine can lower bone density, and the loss may not fully come back. That is why it is generally not recommended for more than 2 years unless other options are inadequate. T...
📖 Read our full Medroxyprogesterone Injection guide →

🕸️ Concept Web — How Medroxyprogesterone acetate 5 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Medroxyprogesterone acetate 5 MG Oral Tablet RxCUI 1000141

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Medroxyprogesterone 6691
    • Medroxyprogesterone acetate 1000112
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Provera 202888
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Medroxyprogesterone Oral Tablet 372739
    • Medroxyprogesterone acetate Oral Tablet 2645848
    • Medroxyprogesterone Oral Product 1159194
    • Medroxyprogesterone Pill 1159195
    • Medroxyprogesterone acetate Oral Product 2660774
    • Medroxyprogesterone acetate Pill 2660079
    • Medroxyprogesterone Oral Tablet [Provera] 93902
    • Medroxyprogesterone acetate Oral Tablet [Provera] 2654826
    • +5 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Medroxyprogesterone acetate 5 MG SCDC · 1000140
  • Medroxyprogesterone Oral Tablet SCDF · 372739
  • Medroxyprogesterone acetate Oral Tablet SCDFP · 2645848
  • Medroxyprogesterone Oral Product SCDG · 1159194
  • Medroxyprogesterone Pill SCDG · 1159195
  • Medroxyprogesterone acetate Oral Product SCDGP · 2660774
  • Medroxyprogesterone acetate Pill SCDGP · 2660079

Brand-Name Concepts

  • Medroxyprogesterone acetate 5 MG Oral Tablet [Provera] SBD · 1000145
  • Medroxyprogesterone acetate 5 MG [Provera] SBDC · 1000144
  • Medroxyprogesterone Oral Tablet [Provera] SBDF · 93902
  • Medroxyprogesterone acetate Oral Tablet [Provera] SBDFP · 2654826
  • Provera Oral Product SBDG · 1182477
  • Provera Pill SBDG · 1182478
  • Provera BN · 202888

📦 FDA Products & Package NDCs

12 products · 18 package NDCs
18 package NDCs map to RxCUI 1000141 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00009-0051-01 100 TABLET in 1 BOTTLE (0009-0051-01) Provera Pharmacia & Upjohn Company LLC 2020-07-20
00009-0065-01 100 TABLET in 1 BOTTLE (0009-0065-01) Provera Pharmacia & Upjohn Company LLC 2019-09-03
00009-0287-01 100 TABLET in 1 BOTTLE (0009-0287-01) Provera Pharmacia & Upjohn Company LLC 2018-11-11
00555-0779-02 100 TABLET in 1 BOTTLE (0555-0779-02) Medroxyprogesterone Acetate Teva Pharmaceuticals USA, Inc. 1996-12-04
00555-0779-04 500 TABLET in 1 BOTTLE (0555-0779-04) Medroxyprogesterone Acetate Teva Pharmaceuticals USA, Inc. 1996-12-04
00555-0872-02 100 TABLET in 1 BOTTLE (0555-0872-02) Medroxyprogesterone Acetate Teva Pharmaceuticals USA, Inc. 1996-12-04
00555-0872-04 500 TABLET in 1 BOTTLE (0555-0872-04) Medroxyprogesterone Acetate Teva Pharmaceuticals USA, Inc. 1996-12-04
00555-0873-02 100 TABLET in 1 BOTTLE (0555-0873-02) Medroxyprogesterone Acetate Teva Pharmaceuticals USA, Inc. 1996-12-04
00555-0873-04 500 TABLET in 1 BOTTLE (0555-0873-04) Medroxyprogesterone Acetate Teva Pharmaceuticals USA, Inc. 1996-12-04
50090-0491-01 30 TABLET in 1 BOTTLE (50090-0491-1) Medroxyprogesterone Acetate A-S Medication Solutions 2016-06-29
59762-0055-01 100 TABLET in 1 BOTTLE (59762-0055-1) medroxyprogesterone acetate Mylan Pharmaceuticals Inc. 2018-08-20
59762-0055-02 1000 TABLET in 1 BOTTLE (59762-0055-2) medroxyprogesterone acetate Mylan Pharmaceuticals Inc. 2020-11-02
59762-0056-01 100 TABLET in 1 BOTTLE (59762-0056-1) medroxyprogesterone acetate Mylan Pharmaceuticals Inc. 2019-06-17
59762-0056-02 1000 TABLET in 1 BOTTLE (59762-0056-2) medroxyprogesterone acetate Mylan Pharmaceuticals Inc. 2020-03-23
59762-0058-01 100 TABLET in 1 BOTTLE (59762-0058-1) medroxyprogesterone acetate Mylan Pharmaceuticals Inc. 2019-01-02
59762-0058-02 1000 TABLET in 1 BOTTLE (59762-0058-2) medroxyprogesterone acetate Mylan Pharmaceuticals Inc. 2020-05-11
63629-8826-01 100 TABLET in 1 BOTTLE (63629-8826-1) Medroxyprogesterone Acetate Bryant Ranch Prepack 1996-12-04
68788-8112-03 30 TABLET in 1 BOTTLE (68788-8112-3) Medroxyprogesterone Acetate Preferred Pharmaceuticals Inc. 2021-12-06
Observed labelers: Mylan Pharmaceuticals Inc. (6) · Teva Pharmaceuticals USA, Inc. (6) · Pharmacia & Upjohn Company LLC (3) · A-S Medication Solutions (1) · Bryant Ranch Prepack (1) · Preferred Pharmaceuticals Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.